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Introduction
Patients with long-standing ulcerative colitis (UC) have an increased risk of developing colorectal cancer (CRC). This neoplasia has a cumulative incidence of 2%, 8% and 18% after 10, 20 and 30 years of disease, respectively [1] . Patients affected by long-standing UC are therefore candidates for surveillance colonoscopy to detect dysplasia [2, 3] . Other than in association with polypoid lesions, dysplasia in UC can also develop in non-polypoid lesions or even within unremarkable mucosa (invisible dysplasia) [4] . Therefore, enhanced optical imaging techniques have been used to facilitate detection of dysplasia in these patients.
Chromo-endoscopy with indigo carmine or methylene blue has been particularly successful in this setting. Indeed, this technique increases the probability of detecting dysplasia by 3 to 5-fold compared to random biopsies [5, 6] , and is now considered a crucial tool in the surveillance of patients with inflammatory bowel diseases (IBD) [7] .
Another contribution to this field was confocal laser endomicroscopy (CLE). This method provides in vivo high-magnified images of microscopic details of the gastrointestinal mucosa thereby enabling a diagnosis of early CR C and detection of dysplasia in UC patients [8, 9] . Chromo-guided CLE has a high accuracy (97.8%) in the diagnosis of neoplastic changes in these patients [10] . Recent years have seen a growing interest in the combined use of targeted probes and new imaging technologies for early detection of cancer. Fluorescein-labeled probes, such as antibodies against neoplastic antigens [11] [12] [13] [14] or phage-derived peptides binding dysplastic tissue [15, 16] have been used in combination with CLE [17] . These latter probes are perhaps the most promising thanks to their low cost and limited immunogenicity, other than the possibility of binding pre-malignant tissue [17] . In-vivo topical application of peptides has been demonstrated to be safe, resulting in accurate staining of adenomatous colonic dysplasia [15] . Consequently, these probes are promising candidates for the detection of dysplasia in surveillance programmes in UC. This is a feasibility pilot study aiming to investigate the potential role of CLE combined with a fluorescent-labeled molecular probe to stain and detect dysplasia in patients with longstanding UC.
Methods

Peptide synthesis and purification
The VRPMPLQ peptide [15] was synthesized on a BiotageSyroWave instrument, a system that combines conventional room temperature and microwaves peptide synthesis, at 25 μmol scale. Fluorescein conjugation was performed at the peptide N-terminus, via an aminohexanoic acid linker, using standard9-fluorenylmethoxycarbonyl (Fmoc) chemistry protocols. Fmocdeprotection was carried out with 25% piperidine in DMF for 5 +10 min at 25˚C.Solutions of Fmoc-AA, HOBT/HBTU, and DIPEA were prepared at concentrations of 0.5M, 0.45M, and 1M in DMF, respectively. Coupling was performed with a 5-fold excess of Fmoc-AA-OH with 1:1:2 AA/HOBT-HBTU/DIPEA for 30 min at 25˚C. Cleavage was carried out with 94:1:2.5:2.5 TFA/ H 2 O/TIS/Thioanisole for 3 hours at 25˚C, followed by precipitation and washings in tert-butyl methyl ether. Peptide analysis and purification were performed with a combined HPLC-ESI +-MS system (high performance liquid chromatography(Gilson, Middleton, WI, USA) coupled with a positiveelectrospray mass spectrometry ionization instrument (FlexarSQ 300 ESI+-MS, Perkin Elmer, Waltham, MA, USA). Analytical RP-HPLC made use of a Jupiter Proteo 10μm C18 250x4.6 mm column (Phenomenex, Torrance, CA, USA), monitoring at 220 and 280 nm, flow rate 1.3 mL/min, and the solvent system H 2 O/0.1% TFA (A) and CH 3 CN/ 0.1% TFA (B), with a linear gradient 5-60% B over 30 min. Peptide purification was performed by semi-preparative RP-HPLC on a Jupiter Proteo 90 Å C18 column (10x250 mm, 10 μm) (Phenomenex, Torrance, CA, USA), using a linear gradient 5-60% B over 25 min, with a flow rate of 10 mL/min. The identity (peptide molecular weight 1311.8) and the peptide purity (98%) were assessed by HPLC-ESI+-MS analysis. MS scan was performed in the mass range 200-3000 m/z. The raw materials used for peptide synthesis and purification are listed in Supporting Infromation, S1 Appendix 1. Lastly, a100 μM solution of VRPMPLQ peptide was prepared.
Patients
Between March 2015 and March 2016, patients undergoing surveillance colonoscopy for longstanding UC and presenting endoscopically resectable lesions within colitis were considered for enrollment. The presence of quiescent UC at endoscopy (Mayo Ulcerative Colitis Endoscopic Score of Severity) [18] was required for inclusion.
Endoscopy
All patients underwent colonoscopy preparation using a polyethylene glycol-based solution. Conscious sedation was obtained by administration of intravenous midazolam. Endoscopic examinations consisted of ileo-colonoscopies and were performed usingOlympus CF-HQ190 or CF TYPE Q180AL/I colonoscopes. After cecal intubation, the colonoscope was slowly withdrawn and the mucosa carefully inspected for endoscopically visible lesions. Lesions were classified according to the ASGE Standards of Practice Committee Guideline for the role of endoscopy in inflammatory bowel disease [19] . Lesions suspicious for dysplasia were evaluated for endoscopic resectability. Polypoid and non-polypoid lesions with distinct borders and without endoscopic features of submucosal invasion were removed en-bloc by endoscopic mucosal resection. Biopsies were obtained from flat and normal appearing mucosa surrounding the resection site.
Ex-vivo tissue imaging
Specimens were rinsed with water and then sprayed with the 100μVRPMPLQ peptide solution within 15 min after excision. After an incubation time of 10 minutes [15] , specimens were rinsed again to remove the excess of peptide not specifically bound to the tissue. CLE examination was then performed, moving the probe close to the mucosal surface of the specimen. The examination was carried-out with the Cellvizio1 Endomicroscopy System (Mauna Kea Technologies, Paris, France), which uses a 2.5-mm catheter probe (Coloflex UHD-type probe). This system has a field of view of 240 x 200 μm, with a lateral resolution of 1 μm. CLE images were collected at a scan rate of 12 frames per second with a scanning field of 30,000 pixels.
At the end of the CLE examination, specimens were fixed in 10% formalin and processed for routine histological examination. Each specimen was classified according to the site of excision and was then assigned a unique number to enable the matching and comparison of histological hematoxylin-eosin sections with the corresponding CLE images.
Mosaic reconstructions were carried out using the Cellvizio1 Viewer software, version 1.6.2 (Mauna Kea Technologies, Paris, France).
Ethical considerations
Patients were excluded in case of age <18 years, refusal to participate or inability to provide written informed consent, which was obtained from all participants. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki (6th revision, 2008) andhas been approved by the "Federico II" University of Naples Institutional Review board-Comitato Etico "C. Romano" (Protocol N.132/2015).
Results
Nine patients were enrolled in the study. All patients had long-standing UC (> 10 years) and presented quiescent UC [18] at surveillance colonoscopy. A total of 11 lesions were obtained from the enrolled patients. In particular, 7 polypoid lesions and 4 non-polypoid were detected at endoscopy and eventually resected. At definitive histology, 4 lesions were diagnosed as inflammatory psudo-polyps, 6 as dysplastic lesions (low-grade dysplasia) and one as invasive cancer (SM3). Table 1 shows the histological characteristics of the collected lesions.
Ex-vivo VRPMPLQ-enhanced CLE
In non-dysplastic mucosa, the fluorescence signal was observed in areas corresponding to peri-cryptal spaces. Crypts were therefore highlighted in negative (Fig 1) .
In case of inflammatory polyps, CLE findings of the lesion together with the flat surrounding tissue were similar to non-dysplastic mucosa, showing passive accumulation of the fluorescent peptide in the enlarged inter-crypt spaces and in the lumen of the crypts (Fig 2) .
On the other hand, in presence of dysplasia, active binding of the peptide to dysplastic colonocytes was observed (Fig 3, Fig 4) .
Discussion
Several studies have assessed the feasibility of detecting colonic dysplasia using targeted fluorescent probes [17] . Antibodies against specific antigens or peptides showing binding affinity for dysplastic tissue have been tested in animal models of CRC [11, 20] and in patients with sporadic adenomas or CRC [13, 15] . In particular, in vivo studies have yielded encouraging results in terms of sensitivity and specificity [15] . In this promising context, the possibility of detecting neoplastic changes associated to IBD using molecular CLE has remained unexplored to date. To our knowledge, this is the first study to assess and confirm the possibility to detect UC-associated dysplasia at ex-vivo CLE examination using a molecular staining probe. In particular, we used the fluorescein-conjugated VRPMPLQ peptide as a molecular probe. This is a phage-derived heptapeptide that has been reported to highlight sporadic colonic dysplasia in vivo during CLE. 15 In this study, for the first time, the VRPMPLQ peptide has demonstrated to be able to detect also the dysplasia associated with Ulcerative Colitis. We believe this result is far from being obvious. Indeed, VRPMPLQ was originally selected because of its binding affinity to sporadic adenomatous polyps [15] . Like most sporadic cancers, sporadic adenomatous polyps are usually sustained by a chromosomal instabilitypathway [21] ,while neoplastic changes in UC are more frequently associated to the microsatellite instability pathway [22] . These different genetic pathways result in different phenotypes [23] that might result in different affinity for this probe, due to differential expression of the molecular target of the VRPMPLQ peptide, that is unknown yet [15] .
In the present study the specificity of the probe for dysplasia areas was corroborated by the different distribution of the peptide observed depending on the absence or presence of dysplasia itself, as determined by traditional histology. In absence of dysplasia, a passive accumulation of the peptide in the lumen crypts and peri-cryptal spaces was observed, as previously described [15] . Thanks to this passive distribution pattern, the tissue architecture (i.e. crypts) is highlighted in negative contrast. Conversely, in the presence of dysplasia, active binding of the peptide to the colonocytes was observed. These findings open new scenarios in the management of lesions discovered in the context of UC. In presence of an endoscopically resectable lesion, topic application of the fluorescent VRPMPLQ peptide could allow a precise definition of the lesion borders, avoiding positive resection margins. Certainly, this theoretical advantage need to be proved by comparative studies on a larger number of lesions. Furthermore, it would allow a detailed examination of the flat mucosa surrounding the lesion, looking for further dysplasia to be discovered, thus orienting biopsies and avoiding unnecessary resections, when not indicated. In addition, topical administration of this molecular contrast avoids intravenous administration of fluorescein, thereby avoiding its adverse systemic effects, and enabling CLE in patients in whom administration of systemic fluorescein is contraindicated [24, 25] .
Further studies on larger population of UC patients are needed to estimate the accuracy and the additional value of targeted CLE compared to chromoendoscopy alone, also in terms of cost/benefits. Indeed, the use of CLE in cancer surveillance remains restricted to suspicious areas highlighted by methylene blue or indigo carmine, because examination of the whole colonic mucosa by CLE remains impracticable [7] . Wanders and colleagues found that the combination of chromoendoscopy and CLE has limited applicability in the surveillance of IBD patients due to a low sensitivity (0.43) [26] . However, their study was hindered by the frequent technique failure of the endoscope-integrated system of CLE (iCLE) used by the authors. The iCLE system integrates the CLE in the tip of the endoscope, in contrast with the probe-based CLE (pCLE), used in this study, where a CLE probe is advanced through the working channel of a standard endoscope. On the contrary, Duglosz and colleagues found good accuracy of pCLE in differentiating neoplastic from non-neoplastic mucosa during surveillance in patients with IBD with high sensitivity (0.89) [26] . A major drawback of the CLE investigation of inflamed mucosa is the risk of false positives for dysplasia due to inflammatory changes as crypt destruction and fluorescein leakage, which can be misdiagnosed as dysplasia [27, 28] . Hence, molecular CLE could improve the specificity of classical CLE in the presence of inflammation thanks to the specificity of the binding probe-dysplasia.
There are several limitations to this study, although most of them are intrinsic to feasibility studies. First, this is a pilot study limited to an ex-vivo investigation, as required by the local ethics committee. Given the experience of Hsiung et al. [15] , we are confident that topical administration in-vivo of the peptide would highlight dysplastic colonocytes in UC patients as well. Nevertheless, this will be the next step of our research. Second, a control peptide was not used to test the specificity of the binding. Indeed, we relied on the observation of Hsiung et al. [15] and the peptide also showed a different pattern of distribution on non-dysplastic lesions. Third, the study was limited to UC patients with quiescent disease. Indeed, the presence of an inflamed mucosa could affect the peptide binding. Increased mucosal permeability and intercrypt distance might favour passive accumulation of the peptide (i.e., non-specific binding), making it difficult to differentiate between active and passive binding. In addition, safety issues might emerge in case of in-vivo administration in patients with active disease. Although peptides have been preferred to antibodies in view of their reduced immunogenicity [17] , the quota of systemic absorption might increase in the presence of altered mucosa. Lastly, we tested the peptide on a small population of lesions in UC patients. These lesions might not account for the entire variety of lesions in terms of genotype and phenotype that might be found in UC patients.
In conclusion, the VRPMPLQ peptide is a promising probe for the detection of dysplasia in the context of IBD. Further in vivo studies on larger populations are required to evaluate the effective contribution of this molecular probe in the management of lesions found during surveillance of UC patients.
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